Xenon Crashed 29% — but the Selloff Prices the Wrong Half of the Company

On Thursday night, Xenon Pharmaceuticals told investors two things at once, and the market heard only one of them. The first: its lead drug, azetukalner, had reached the FDA — a New Drug Application for the most common type of epileptic seizure, submitted September 17. The second: it was voluntarily pausing new enrollment in its major-depression and bipolar-depression trials after patients developed neuropsychiatric side effects. By midday Friday the stock had fallen 29%, from Thursday's close of $57.35 to about $40.60, a six-month low that erased every gain since the big epilepsy readout in March.

That juxtaposition — the company's most valuable milestone landing on the same day a setback struck a lower-confidence program — is the whole story. Because azetukalner is one molecule being developed for two very different businesses. The crash wasn't a uniform markdown of the company. It was the market pricing down the half that deserved it.

Two assets in one body

Sort the molecule into its two uses and the picture separates cleanly.

The epilepsy franchise is the value driver. In March, the Phase 3 X-TOLE2 trial in highly treatment-resistant focal seizures met its goal: a 25-mg daily dose cut median seizure frequency 53.2% over 12 weeks versus 10.4% for placebo — a 42.7-percentage-point placebo-adjusted reduction, the strongest such result in a pivotal epilepsy study, with an over-50%-response rate (54.8% versus 20.8% for placebo) roughly 2.6 times placebo. More than 1,500 patient-years of safety and exposure support the program. If approved, it's first-in-class — the only KV7 potassium-channel opener for epilepsy — and Jefferies has its sights on $2 billion-plus in peak epilepsy sales. The FDA decision is penciled in for around September 2027.

The psychiatry franchise is the option. That's where the adverse events appeared in the Phase 3 depression and bipolar trials: confusion, aphasia, ataxia, and a single psychosis case — events that hadn't shown up in the earlier Phase 2 depression study. Patients already enrolled stay on therapy; the company is evaluating dose modifications to improve tolerability.

Now the telling part: the pause does not touch the epilepsy program. The NDA is in. The vast safety database belongs to epilepsy. Analysts at RBC Capital Markets cut their target to $70 from $81 but were explicit that the pause "should not impact" the value-driving epilepsy indication or the promised launch next year — the depression commercial opportunity is now, in RBC's words, "a bit more diminished."

Bought the wrong half — or the right one?

The reflexive read — "it crashed, so it's cheap" — is the wrong instinct here, and not because the crash was without cause. It had a cause: the depression program was real, option-like upside, and that upside is now smaller. Dose adjustments may fix the tolerability; they aren't guaranteed. The X-NOVA2 depression readout slipped to Q1 2027, and its enrollment closed early at roughly 360 of a planned 450. Anyone who bought this as both an epilepsy drug and a depression drug in one share has lost a piece of that second purchase.

But the market's 29% markdown treated a de-risked option as though it had infected the thing that actually matters. It didn't. The base of the value — the epilepsy launch — survived the news untouched. Put differently: strip out the depression story entirely and value the company on the epilepsy franchise plus its $1.34-billion cash cushion, with a runway through 2029, and most of the value the shares held before Friday was already that epilepsy business.

That's the irony the crash masks. A stock that fell a third on a psychiatry setback is, at its core, an epilepsy-and-cash story that didn't change. The depression program was upside on top; it's now a smaller, later, less certain bonus — which is more or less what the analysts priced in.

What changes the read

None of this makes the stock "cheap," and it would be a mistake to pretend it is. This is a single-asset biopharma: the entire valuation still rests on one FDA decision that doesn't land until about September 2027, and a 14.5% discontinuation rate in the top-dose epilepsy arm is a quiet tolerance red flag, not a rounding error. The cash runway buys time, not approval.

So the honest answer to "is now the time to buy" is: the crash priced the disappointment correctly and hasn't damaged the part of the company that carries the value — but that alone is not a signal, because the deciding facts haven't arrived. The lead indicators here are the dose-modification plan, the Q1 2027 depression readout, and the FDA's handling of a filed NDA built on the strongest efficacy data in the field. When those converge, the trade gets its data. Until then, buying the dip on conviction that the market overreacted is a guess with a plausible mechanism — and in a single-molecule biotech, conviction without the data is just guts wearing a costume.